1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010 Sep–Oct;60(5):277–300.
2. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002 May 15;94(10):2766–2792.
3. Ohlsson B, Palsson B. Follow-up after colorectal cancer surgery.
Acta Oncol. 2003;42(8):816–826.
[PubMed: 14968942]
4. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986 Nov;150(3):195–203.
5. Kang MC, Kang CH, Lee HJ, Goo JM, Kim YT, Kim JH. Accuracy of 16-channel multi-detector row chest computed tomography with thin sections in the detection of metastatic pulmonary nodules. Eur J Cardiothorac Surg. 2008 Mar;33(3):473–479.
6. Engstrom PF, Arnoletti JP, Benson AB, 3rd, et al. NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw. 2009 Sep;7(8):778–831.
7. Engstrom PF, Arnoletti JP, Benson AB, 3rd, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009 Sep;7(8):838–881.
8. Dobos N, Rubesin SE. Radiologic imaging modalities in the diagnosis and management of colorectal cancer. Hematol Oncol Clin North Am. 2002 Aug;16(4):875–895.
9. Gonzalez-Moreno S, Gonzalez-Bayon L, Ortega-Perez G, Gonzalez-Hernando C. Imaging of peritoneal carcinomatosis. Cancer J. 2009 May–Jun;15(3):184–189.
10. Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology. 2010 Dec;257(3):674–684.
11. Patel CN, Goldstone AR, Chowdhury FU, Scarsbrook AF. FDG PET/CT in oncology: “raising the bar”. Clin Radiol. 2010 Jul;65(7):522–535.
12. Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol. 2009 Jun;70(3):382–392.
13. Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis.
J Magn Reson Imaging. 2010;31(1):19–31.
[PubMed: 20027569]
14. Joyce DL, Wahl RL, Patel PV, Schulick RD, Gearhart SL, Choti MA. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg. 2006 Dec;141(12):1220–1226; discussion 1227.
15. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004 Dec;240(6):1027–1034; discussion 1035–1026.
16. Wiering B, Krabbe PF, Jager GJ, Oyen WJ, Ruers TJ. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer. 2005 Dec 15;104(12): 2658–2670.
17. Pawlik TM, Assumpcao L, Vossen JA, et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol. 2009 Feb;16(2):371–378.
18. Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal liver metastases and of other liver malignancies. Ann Surg Oncol. 2003 Nov;10(9):1007–1011.
19. Grobmyer SR, Wang L, Gonen M, et al. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg. 2006 Aug;244(2):260–264.
20. Laurent C, Sa Cunha A, Rullier E, Smith D, Rullier A, Saric J. Impact of microscopic hepatic lymph node involvement on survival after resection of colorectal liver metastasis. J Am Coll Surg. 2004 Jun;198(6):884–891.
21. Wildi SM, Gubler C, Hany T, et al. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT. J Clin Ultrasound. 2008 Jan;36(1):20–26.
22. van Vledder MG, Pawlik TM, Munireddy S, Hamper U, de Jong MC, Choti MA. Factors determining the sensitivity of intraoperative ultrasonography in detecting colorectal liver metastases in the modern era. Ann Surg Oncol. 2010 Oct;17(10):2756–2763.
23. van Vledder MG, Torbenson MS, Pawlik TM, et al. The effect of steatosis on echogenicity of colorectal liver metastases on intraoperative ultrasonography. Arch Surg. 2010 Jul;145(7):661–667.
24. Choti MA, Kaloma F, de Oliveira ML, et al. Patient variability in intraoperative ultrasonographic characteristics of colorectal liver metastases. Arch Surg. 2008 Jan;143(1):29–34; discussion 35.
25. Torzilli G, Del Fabbro D, Palmisano A, et al. Surgical strategy for liver tumors located at the hepato-caval confluence. Ann Ital Chir. 2006 Jul–Aug;77(4):323–328.
26. Poon RT. Recent advances in techniques of liver resection.
Surg Technol Int. 2004;13:71–77.
[PubMed: 15744678]
27. Patel NA, Roh MS. Utility of intraoperative liver ultrasound. Surg Clin North Am. 2004 Apr;84(2):513–524.
28. Hur H, Lee HH, Jung H, Song KY, Jeon HM, Park CH. Predicting factors of unexpected peritoneal seeding in locally advanced gastric cancer: indications for staging laparoscopy. J Surg Oncol. 2010 Dec 1;102(7):753–757.
29. Muntean V, Mihailov A, Iancu C, et al. Staging laparoscopy in gastric cancer. Accuracy and impact on therapy. J Gastrointestin Liver Dis. 2009 Jun;18(2):189–195.
30. Hariharan D, Constantinides
VA, Froeling FE, Tekkis PP, Kocher HM. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers—a meta-analysis.
Eur J Surg Oncol. 2010 Oct;36(10):941–948.
31. Samee A, Moorthy K, Jaipersad T, et al. Evaluation of the role of laparoscopic ultrasonography in the staging of oesophagogastric cancers. Surg Endosc. 2009 Sep;23(9):2061–2065.
32. Pilkington SA, Rees M, Peppercorn D, John TG. Laparoscopic staging in selected patients with colorectal liver metastases as a prelude to liver resection.
HPB (Oxford). 2007;9(1):58–63.
[PubMed: 18333114]
33. Jarnagin WR, Conlon K, Bodniewicz J, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer. 2001 Mar 15;91(6):1121–1128.
34. Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006 Oct;13(10):1261–1268.
35. Pawlik TM, Choti MA. Shifting from clinical to biologic indicators of prognosis after resection of hepatic colorectal metastases. Curr Oncol Rep. 2007 May;9(3):193–201.
36. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008 Jan;13(1):51–64.
37. Lupinacci R, Penna C, Nordlinger B. Hepatectomy for resectable colorectal cancer metastases—indicators of prognosis, definition of resectability, techniques and outcomes. Surg Oncol Clin N Am. 2007 Jul;16(3): 493–506, vii–viii.
38. Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin N Am. 2003 Jan;12(1):165–192, xi.
39. Kokudo N, Imamura H, Sugawara Y, et al. Surgery for multiple hepatic colorectal metastases.
J Hepatobiliary Pancreat Surg. 2004;11(2):84–91.
[PubMed: 15127269]
40. Weber SM, Jarnagin WR, DeMatteo RP, Blumgart LH, Fong Y. Survival after resection of multiple hepatic colorectal metastases. Ann Surg Oncol. 2000 Oct;7(9):643–650.
41. Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg. 2005 May;241(5):715–722, discussion 722–714.
42. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg. 2008 Oct;248(4):626–637.
43. Elias DM, Ouellet JF. Incidence, distribution, and significance of hilar lymph node metastases in hepatic colorectal metastases. Surg Oncol Clin N Am. 2003 Jan;12(1):221–229.
44. Byam J, Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RC. Should hepatic metastatic colorectal cancer patients with extrahepatic disease undergo liver resection/ablation? Ann Surg Oncol. 2009 Nov;16(11):3064–3069.
45. Carpizo DR, Are C, Jarnagin W, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol. 2009 Aug;16(8):2138–2146.
46. de Haas RJ, Wicherts DA, Adam R. Resection of colorectal liver metastases with extrahepatic disease. Dig Surg. 2008;25(6):461–466.
47. Elias D, Liberale G, Vernerey D, et al. Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect. Ann Surg Oncol. 2005 Nov;12(11):900–909.
48. Schroeder RA, Marroquin CE, Bute BP, Khuri S, Henderson WG, Kuo PC. Predictive indices of morbidity and mortality after liver resection. Ann Surg. 2006 Mar;243(3):373–379.
49. Komori H, Beppu T, Baba Y, et al. Histological liver injury and surgical outcome after
FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients.
Int J Clin Oncol. 2010 Jun;15(3):263–270.
50. Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009 Aug 27;145(1):9–19.
51. Abulkhir A, Limongelli P, Healey AJ, et al. Preoperative portal vein embolization for major liver resection: a meta-analysis. Ann Surg. 2008 Jan;247(1):49–57.
52. Vauthey JN, Chaoui A, Do KA, et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery. 2000 May;127(5):512–519.
53. Aloia TA, Fahy BN, Fischer CP, et al. Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford). 2009 Sep;11(6):510–515.
54. Celinski SA, Gamblin
TC. Hepatic resection nomenclature and techniques.
Surg Clin North Am. 2010 Aug;90(4):737–748.
55. Couinaud CM. A simplified method for controlled left hepatectomy. Surgery. 1985 Mar;97(3):358–361.
56. DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg. 2000 Mar–Apr;4(2):178–184.
57. Pamecha V, Gurusamy KS, Sharma D, Davidson BR. Techniques for liver parenchymal transection: a meta-analysis of randomized controlled trials. HPB (Oxford). 2009 Jun;11(4):275–281.
58. Sugo H, Mikami Y, Matsumoto F, et al. Hepatic resection using the harmonic scalpel.
Surg Today. 2000;30(10):959–962.
[PubMed: 11059743]
59. Geller DA, Tsung A, Maheshwari V, Rutstein LA, Fung JJ, Marsh JW. Hepatic resection in 170 patients using saline-cooled radiofrequency coagulation.
HPB (Oxford). 2005;7(3):208–213.
[PubMed: 18333192]
60. Pai M, Jiao LR, Khorsandi S, Canelo R, Spalding DR, Habib NA. Liver resection with bipolar radiofrequency device: Habib 4X.
HPB (Oxford). 2008;10(4):256–260.
[PubMed: 18773112]
61. Schemmer P, Friess H, Hinz U, et al. Stapler hepatectomy is a safe dissection technique: analysis of 300 patients. World J Surg. 2006 Mar;30(3):419–430.
62. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002 Jun;235(6):759–766.
63. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep;230(3):309–318; discussion 318–321.
64. Vauthey JN, Pawlik TM, Abdalla EK, et al. Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg. 2004 May;239(5):722–730; discussion 730–722.
65. Choti MA, Bowman HM, Pitt HA, et al. Should hepatic resections be performed at high-volume referral centers? J Gastrointest Surg. 1998 Jan–Feb;2(1):11–20.
66. de Liguori Carino N, van Leeuwen BL, Ghaneh P, Wu A, Audisio RA, Poston GJ. Liver resection for colorectal liver metastases in older patients. Crit Rev Oncol Hematol. 2008 Sep;67(3):273–278.
67. Farid SG, Aldouri A, Morris-Stiff G, et al. Correlation between postoperative infective complications and long-term outcomes after hepatic resection for colorectal liver metastasis. Ann Surg.2010 Jan;251(1): 91–100.
68. Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007 Nov;246(5):806–814.
69. Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg. 1992 Oct;216(4):493–504; discussion 504–495.
70. Adam R, Frilling A, Elias D, et al. Liver resection of colorectal metastases in elderly patients. Br J Surg. 2010 Mar;97(3):366–376.
71. Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990 Nov;77(11):1241–1246.
72. Hughes KS, Rosenstein RB, Songhorabodi S, et al. Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors. Dis Colon Rectum. 1988 Jan;31(1):1–4.
73. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004 Jun;239(6):818–825; discussion 825–817.
74. de Haas RJ, Wicherts DA, Salloum C, et al. Long-term outcomes after hepatic resection for colorectal metastases in young patients. Cancer. 2010 Feb 1;116(3):647–658.
75. House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010 May;210(5):744–752, 752–745.
76. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996 Apr 1;77(7):1254–1262.
77. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009 Sep;250(3):440–448.
78. Bilchik AJ, Poston G, Adam R, Choti MA. Prognostic variables for resection of colorectal cancer hepatic metastases: an evolving paradigm. J Clin Oncol. 2008 Nov 20;26(33):5320–5321.
79. Gayowski TJ, Iwatsuki S, Madariaga JR, et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery. 1994 Oct;116(4):703–710; discussion 710–701.
80. Are C, Gonen M, Zazzali K, et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg. 2007 Aug; 246(2):295–300.
81. Nuzzo G, Giuliante F, Ardito F, et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery. 2008 Mar;143(3):384–393.
82. Inoue M, Ohta M, Iuchi K, et al. Benefits of surgery for patients with pulmonary metastases from colorectal carcinoma. Ann Thorac Surg. 2004 Jul;78(1):238–244.
83. Sakamoto T, Tsubota N, Iwanaga K, Yuki T, Matsuoka H, Yoshimura M. Pulmonary resection for metastases from colorectal cancer. Chest. 2001 Apr;119(4):1069–1072.
84. Headrick JR, Miller DL, Nagorney DM, et al. Surgical treatment of hepatic and pulmonary metastases from colon cancer. Ann Thorac Surg. 2001 Mar;71(3):975–979; discussion 979–980.
85. Neeff H, Horth W, Makowiec F, et al. Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg. 2009 Oct;13(10):1813–1820.
86. Mineo
TC, Ambrogi V, Tonini G, et al. Long-term results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma.
J Am Coll Surg. 2003 Sep;197(3):386–391.
87. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999 Sep;189(3):291–299.
88. Viana EF, Herman P, Siqueira SC, et al. Lymphadenectomy in colorectal cancer liver metastases resection: incidence of hilar lymph nodes micrometastasis. J Surg Oncol. 2009 Dec 1;100(7):534–537.
89. Bennett JJ, Schmidt CR, Klimstra DS, et al. Perihepatic lymph node micrometastases impact outcome after partial hepatectomy for colorectal metastases. Ann Surg Oncol. 2008 Apr;15(4):1130–1136.
90. Yan TD, Morris DL. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for isolated colorectal peritoneal carcinomatosis: experimental therapy or standard of care? Ann Surg. 2008 Nov;248(5):829–835.
91. Chua
TC, Yan TD, Zhao J, Morris DL. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection.
Eur J Surg Oncol. 2009 Dec;35(12):1299–1305.
92. Elias D, Ouellet JF, Bellon N, Pignon JP, Pocard M, Lasser P. Extrahepatic disease does not contraindicate hepatectomy for colorectal liver metastases. Br J Surg. 2003 May;90(5):567–574.
93. de Gramont A, Figer A, Seymour M, et al. Leucovorin and
fluorouracil with or without
oxaliplatin as first-line treatment in advanced colorectal cancer.
J Clin Oncol. 2000 Aug;18(16):2938–2947.
94. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of
irinotecan plus supportive care versus supportive care alone after
fluorouracil failure for patients with metastatic colorectal cancer.
Lancet. 1998 Oct 31;352(9138):1413–1418.
95. Douillard JY, Cunningham D, Roth AD, et al.
Irinotecan combined with
fluorouracil compared with
fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet. 2000 Mar 25;355(9209):1041–1047.
96. Hurwitz H, Fehrenbacher L, Novotny W, et al.
Bevacizumab plus
irinotecan,
fluorouracil, and leucovorin for metastatic colorectal cancer.
N Engl J Med. 2004 Jun 3;350(23):2335–2342.
97. Van Cutsem E, Kohne CH, Hitre E, et al.
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
N Engl J Med. 2009 Apr 2;360(14):1408–1417.
98. Andre T, Boni C, Navarro M, et al. Improved overall survival with
oxaliplatin,
fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
J Clin Oncol. 2009 Jul 1;27(19):3109–3116.
99. O'Connell MJ, Laurie JA, Kahn M, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998 Jan;16(1):295–300.
100. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of
fluorouracil plus leucovorin,
irinotecan, and
oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
J Clin Oncol. 2004 Jan 1;22(1):23–30.
101. Mitry E, Fields AL, Bleiberg H, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol. 2008 Oct 20; 26(30):4906–4911.
102. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant
fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.
J Clin Oncol. 2006 Nov 1;24(31):4976–4982.
103. Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006 Mar 20;24(9):1395–1403.
104. Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with
floxuridine (FUDR) and
dexamethasone plus systemic
oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
Ann Oncol. 2009 Jul;20(7):1236–1241.
105. Allen PJ, Kemeny N, Jarnagin W, DeMatteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg. 2003 Jan;7(1):109–115; discussion 116–107.
106. Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004 Dec;240(6):1052–1061; discussion 1061–1054.
107. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with
bevacizumab for colorectal liver metastases.
JAMA. 2009 Dec 2;302(21):2338–2344.
108. Blazer DG, 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008 Nov 20;26(33):5344–5351.
109. Tamandl D, Klinger M, Eipeldauer S, et al. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Ann Surg Oncol. 2011 Feb;18(2):421–430.
110. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007 Jul;11(7):860–868.
111. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg. 2007 Mar;94(3):274–286.
112. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with
irinotecan or
oxaliplatin pretreatment on resectability of hepatic colorectal metastases.
J Am Coll Surg. 2005 Jun;200(6):845–853.
113. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010 Nov;14(11):1691–1700.
114. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006 Aug 20;24(24):3939–3945.
115. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with
FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.
Lancet. 2008 Mar 22;371(9617): 1007–1016.
116. Tournigand C, Andre T, Achille E, et al.
FOLFIRI followed by
FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
J Clin Oncol. 2004 Jan 15;22(2):229–237.
117. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional
fluorouracil,
irinotecan, and
bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.
J Clin Oncol. 2010 Jan 20;28(3):453–459.
118. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of
cetuximab in combination with
fluorouracil, leucovorin, and
oxaliplatin in the first-line treatment of metastatic colorectal cancer.
J Clin Oncol. 2007 Nov 20;25(33):5225–5232.
119. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin,
oxaliplatin, and
irinotecan (
FOLFOXIRI) followed by radical surgery of metastases.
Ann Surg. 2009 Mar;249(3):420–425.
120. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004 Oct;240(4):644–657; discussion 657–648.
121. Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005 Aug;16(8):1311–1319.
122. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with
cetuximab: the CELIM randomised phase 2 trial.
Lancet Oncol. 2010 Jan;11(1):38–47.
123. Wong SL, Mangu PB, Choti MA, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010 Jan 20;28(3):493–508.
124. Gillams AR, Lees WR. Radiofrequency ablation of colorectal liver metastases. Abdom Imaging. 2005 Jul–Aug;30(4):419–426.
125. van Duijnhoven FH, Jansen MC, Junggeburt JM, et al. Factors influencing the local failure rate of radiofrequency ablation of colorectal liver metastases. Ann Surg Oncol. 2006 May;13(5):651–658.
126. Schraml C, Clasen S, Schwenzer NF, et al. Diagnostic performance of contrast-enhanced computed tomography in the immediate assessment of radiofrequency ablation success in colorectal liver metastases. Abdom Imaging. 2008 Nov–Dec;33(6):643–651.
127. Kuehl H, Antoch G, Stergar H, et al. Comparison of FDG-PET, PET/CT and MRI for follow-up of colorectal liver metastases treated with radiofrequency ablation: initial results. Eur J Radiol. 2008 Aug;67(2):362–371.
128. Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg. 2008 Dec;143(12):1204–1212.
129. Ruers TJ, Joosten JJ, Wiering B, et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol. 2007 Mar;14(3):1161–1169.
130. Ackerman NB, Hodgson WB. Vascular patterns of liver tumors and their consequences for different therapeutic approaches.
Recent Results Cancer Res. 1986;100:248–255.
[PubMed: 3738165]
131. Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983 Jun;10(2):176–182.
132. Kemeny NE. Regional chemotherapy of colorectal cancer. Eur J Cancer. 1995 Jul–Aug;31A(7–8):1271–1276.
133. Kemeny N, Daly J, Reichman B, Geller N, Botet J, Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987 Oct;107(4):459–465.
134. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg. 1987 Dec;206(6):685–693.
135. Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial
floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial.
J Clin Oncol. 1989 Nov;7(11):1646–1654.
136. Kerr DJ, McArdle CS, Ledermann J, et al. Intrahepatic arterial versus intravenous
fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
Lancet. 2003 Feb 1; 361(9355):368–373.